Squarepoint Ops LLC Acquires Shares of 162,415 Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Squarepoint Ops LLC acquired a new stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 162,415 shares of the biopharmaceutical company's stock, valued at approximately $5,337,000. Squarepoint Ops LLC owned approximately 0.28% of Agios Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after acquiring an additional 85,339 shares in the last quarter. Jefferies Financial Group Inc. acquired a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. Fisher Asset Management LLC raised its position in shares of Agios Pharmaceuticals by 12.3% during the 4th quarter. Fisher Asset Management LLC now owns 960,661 shares of the biopharmaceutical company's stock worth $31,567,000 after purchasing an additional 105,333 shares during the last quarter. Deutsche Bank AG raised its position in shares of Agios Pharmaceuticals by 39.7% during the 4th quarter. Deutsche Bank AG now owns 935,252 shares of the biopharmaceutical company's stock worth $30,732,000 after purchasing an additional 265,637 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC raised its position in shares of Agios Pharmaceuticals by 3.9% during the 4th quarter. ArrowMark Colorado Holdings LLC now owns 917,420 shares of the biopharmaceutical company's stock worth $30,146,000 after purchasing an additional 34,689 shares during the last quarter.

Agios Pharmaceuticals Stock Up 0.9%

Shares of AGIO stock traded up $0.29 on Friday, reaching $32.13. 117,935 shares of the stock were exchanged, compared to its average volume of 679,555. The stock has a market cap of $1.86 billion, a P/E ratio of 2.83 and a beta of 0.77. The firm has a 50 day moving average of $28.55 and a two-hundred day moving average of $35.44. Agios Pharmaceuticals, Inc. has a 1-year low of $23.42 and a 1-year high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. The business had revenue of $8.73 million during the quarter, compared to the consensus estimate of $9.86 million. On average, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Scotiabank cut their price objective on Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a research report on Friday, May 2nd. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research report on Monday, February 24th. They set a "buy" rating and a $58.00 price objective for the company. Finally, Wall Street Zen downgraded Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $56.00.

Insider Buying and Selling

In other Agios Pharmaceuticals news, Director Jacqualyn A. Fouse sold 7,497 shares of the company's stock in a transaction dated Thursday, April 10th. The shares were sold at an average price of $25.90, for a total value of $194,172.30. Following the completion of the transaction, the director now directly owns 149,220 shares of the company's stock, valued at $3,864,798. This represents a 4.78% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 4.30% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.